Fermenta Biotech reported a consolidated net profit of ₹9.5 crore for the quarter ended June 30, 2026 (Q1FY27), marking a 56% decline year-on-year. The significant drop in profitability was primarily attributed to a 40% fall in Vitamin D3 – Animal Nutrition realisations and the absence of ₹2.7 crore in non-recurring insurance income that had boosted the prior year’s base. Consolidated revenue, including real estate value unlocking, stood at ₹126.2 crore, down 13% YoY but flat quarter-on-quarter. Excluding real estate, core business revenue was ₹124.3 crore, down 12% YoY.

The company’s EBITDA (excluding real estate) was ₹22.3 crore, down 37% YoY and 10% QoQ. On a consolidated basis including real estate, EBITDA was ₹22.4 crore, down 39% YoY. Diluted earnings per share were ₹3.34. Management noted that the year-on-year comparison is set against an exceptionally strong April–June 2025 quarter, which included one-time items such as ₹1.6 crore from real estate value unlocking and higher other income. A write-back of ₹2.0 crore from slow-moving semi-finished inventory in animal feed production was included in the reported EBITDA.

Segment Performance

The human nutrition segment remained the largest contributor, accounting for 61% of consolidated revenue with sales of ₹76.5 crore. While human nutrition volumes rose 18% QoQ, revenue in this segment fell 10% YoY to ₹76.5 crore. In contrast, the animal nutrition segment faced headwinds, with revenue dropping 41% YoY to ₹12.6 crore due to a 40% decline in average realisations. Volumes in animal nutrition were down 52% QoQ and 20% YoY.

Other business lines showed growth. Other APIs and Intermediates revenue grew 18% YoY to ₹11.6 crore, while Green Chemistry Solutions / Enzymes rose 15% YoY to ₹2.3 crore. The 'Others' line within nutrition grew 28% YoY to ₹11.0 crore. Environmental Solutions revenue surged 619% QoQ to ₹6.0 crore, though it declined 8% YoY.

Geographical Shifts

India emerged as a stronger market, contributing 47% of consolidated revenue (excluding real estate) in Q1FY27, up from 35% a year earlier and 38% in the preceding quarter. Europe’s share declined to 23% from 33% YoY, while North America accounted for 10%. This shift reflects growing domestic demand and successful customer acquisitions in smaller business lines.

Cost Structure Dynamics

Raw material costs improved to 35% of revenue in Q1FY27, against 37% in FY26 and 38% in FY25, reflecting an improved sourcing mix. However, employee costs rose to 19% of revenue, compared to 16% in FY26, when capacity expansion added heads ahead of the Dahej scale-up. Manufacturing expenses remained stable at 12%, consistent with FY26 levels but lower than the 15% recorded in FY25. Finance costs held steady at 2% of revenue, indicating continued deleveraging efforts.

What the Numbers Show

The divergence between volume growth in human nutrition and declining revenue highlights pricing pressures or mix shifts within the core segment. While human nutrition volumes grew 18% QoQ, the segment’s revenue contribution fell 10% YoY, suggesting that higher volumes did not fully offset price declines or currency impacts. Meanwhile, the sharp contraction in animal nutrition realisations (-40% YoY) indicates continued softness in feed ingredient prices, forcing management to prioritize volume discipline over chasing weak prices. The rise in India’s revenue share to 47% signals a strategic pivot towards domestic markets, reducing reliance on volatile international segments like Europe, which saw its share drop by 10 percentage points YoY.

Operational Updates

Prashant Nagre, Managing Director, stated that the quarter was about “building rather than harvesting,” emphasizing growth in emerging segments like Green Chemistry and Other APIs. Post-quarter, Fermenta received FSSAI approval on July 6, 2026, for VITADEE Green®, its plant-source Vitamin D3, for use in health supplements and food fortification. This approval opens access to India’s large vegetarian consumer base. Additionally, the company ranked 7th nationwide in the Top 50 category of India’s Great Mid-size Workplaces™ 2026.

Fermenta Biotech reported a sharp contraction in consolidated profitability for the quarter ended June 30, 2026, driven by declining revenues in its core bulk drugs segment and the absence of exceptional items that had boosted prior-year figures. Standalone net profit after tax (PAT) decreased 7.70% year-on-year (YoY) to ₹1,498.58 lakhs from ₹1,623.38 lakhs in Q1FY25. The consolidated net profit suffered a steeper decline of 55.80% YoY, falling to ₹953.15 lakhs compared to ₹2,160.17 lakhs in the corresponding period last year.

The Board of Directors approved the unaudited financial results on August 11, 2026, pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. M/s. SRBC & Co. LLP, the statutory auditors, issued a limited review report with an unmodified opinion on both standalone and consolidated results. Managing Director Prashant Nagre signed off on the filings, which were submitted to the Bombay Stock Exchange and National Stock Exchange of India Limited.

Financial Performance Highlights

Revenue from operations showed weakness across both reporting structures. Standalone revenue from operations declined 6.0% YoY to ₹11,183.93 lakhs from ₹11,901.87 lakhs. On a consolidated basis, revenue dropped 10.60% YoY to ₹12,182.12 lakhs from ₹13,626.27 lakhs. Total income followed a similar trajectory, with standalone total income falling 8.70% to ₹11,673.59 lakhs and consolidated total income decreasing 12.90% to ₹12,619.50 lakhs.

The following table summarises key financial metrics across both standalone and consolidated reporting structures for the quarter:

Profit before tax for the standalone entity remained relatively stable at ₹2,014.58 lakhs, down slightly from ₹2,271.92 lakhs in Q1FY25. However, the consolidated profit before tax collapsed 47.70% YoY to ₹1,469.15 lakhs from ₹2,808.71 lakhs. This divergence highlights the impact of foreign subsidiaries and inter-segment dynamics on the group's overall performance.

What the Numbers Show

The disparity between standalone and consolidated results underscores the pressure on Fermenta Biotech's international operations. While the Indian parent company maintained its profit before tax levels, the consolidated entity faced a severe earnings compression. A key factor was the absence of exceptional items in the current quarter; the previous year's comparable period benefited from a ₹907.14 lakh recovery of provisions against receivables, recorded as an exceptional item but impacting the comparative base for growth calculations. Additionally, the consolidated segment results reveal that the 'Unallocated' category posted a net loss of ₹188.83 lakhs, compared to a profit of ₹210.03 lakhs in Q1FY25, further dragging down group profitability. The bulk drugs/chemicals segment, the primary revenue driver, saw its segment result decline 30.80% YoY on a consolidated basis from ₹2,752.23 lakhs to ₹1,905.05 lakhs, indicating margin erosion or volume declines in core products.